News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The company has received the GMP Certification after successful closure of the inspection
Aims to achieve CDMO sales of US$ 400 million by 2028
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
ANVISA issues CGMP to Concord Biotech’s Unit I
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
